Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

NCT06163430 is registered in ClinicalTrials.gov with Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.

NCT NCT06163430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06163430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 26, 2024
Completion date
May 31, 2030
Enrollment
180 (estimated)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic myeloid leukemia, chronic phase